A Phase 2, Multi-Center, Open-label, Randomized, Parallel-Group Study of A Lenalidomide (Revlimid??) Regimen or A Sequential Azacitidine (Vidaza??) plus Lenalidomide (Revlimid??) Regimen versus Leukemia (CC-5013-AML-001)
|Effective start/end date||10/17/12 → 12/31/17|
- Celgene Corporation
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.